CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with ...

Wave currently has four drugs in development, but I'll focus on WVE-N531. This drug aims to treat Duchenne Muscular Dystrophy ...

Wave Life Sciences WVE announced positive interim data from a mid-stage study evaluating its investigational candidate, ...

The company’s candidate, WVE-N531, a treatment specifically designed for patients with a mutation in exon 53 of the dystrophin gene. It is a type of gene therapy that aims to restore the ...

Apart from the AATD indication, there are several other candidates like WVE-N531, WVE-003 and WVE-007 in Wave Life Sciences’ pipeline, which are being developed for rare and prevalent diseases ...

The company’s candidate, WVE-N531, a treatment specifically designed for patients with a mutation in exon 53 of the dystrophin gene. It is a type of gene therapy that aims to restore the ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Sanofi shares added 0.4%. Wave Life Sciences (WVE) shares surged past 53% after the company reported "positive" interim data from a phase 2 trial of WVE-N531 to treat boys with Duchenne muscular ...

The adjustment follows the recent disclosure of promising data from the company's Duchenne muscular dystrophy (DMD) drug candidate, WVE-N531. The analyst cited increased confidence in the company's ...

Interim phase II data of Wave Life Sciences Ltd.’s oligonucleotide, WVE-N531, revealed “impressive” dystrophin expression, solid safety and the potential for once-monthly dosing for boys with Duchenne ...